Herbal granules aim to lift mood in transplant survivors
NCT ID NCT07608029
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether Xiaochaihu Granules, a traditional Chinese herbal medicine, can help with depression in people who have had a stem cell transplant. About 46 patients will receive either a low or high dose of the granules for 100 days, alongside standard care. Researchers will track mood changes, side effects, and transplant-related complications.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Xiaochaihu Granules (a traditional Chinese medicine herbal formula)
- What this could lead to
- If it works, this could offer a new option to ease depression in people recovering from a stem cell transplant, without adding strong side effects.
- What could go wrong
- This is a small, early-phase trial with only 46 people, so results may not apply widely. The herbal granules may not work better than standard care, and long-term safety is unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 46 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
14 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants must meet all of the following criteria: 1. Able to understand the study procedures and voluntarily provide written informed consent (or consent from a legal guardian where applicable); 2. Age ≥14 years, male or female; 3. Patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT); 4. Newly diagnosed depression after allo-HSCT, assessed by standardized scales (e.g., HADS and/or HAMD); 5. Evidence of successful neutrophil engraftment prior to enrollment; 6. Willing and able to comply with study procedures and follow-up assessments. Exclusion Criteria: 1. Refusal to participate in the study; 2. Presence of severe psychiatric disorders or severe somatic symptom disorders; 3. Known allergy to Xiaochaihu Granules or any of its components; 4. Current use of other antidepressant medications; 5. Severe organ dysfunction or unstable clinical condition, including but not limited to: Uncontrolled bloodstream infection; Expected survival \<3 months; 6. History of splenectomy; 7. Renal insufficiency with serum creatinine ≥2.0 mg/dL; 8. Cholestatic liver disease or unresolved hepatic veno-occlusive disease (VOD); 9. Significant cardiovascular conditions, including: Unstable angina; Acute myocardial infarction within 6 months prior to enrollment; NYHA class III-IV heart failure; Circulatory failure requiring vasoactive or inotropic support; Clinically significant arrhythmia requiring treatment; 10. Severe respiratory disease requiring mechanical ventilation or ≥50% oxygen support; 11. Patients whose primary disease is in complete remission after transplantation (per protocol definition); 12. Participation in another interventional clinical trial within 21 days prior to enrollment (or within 5 half-lives of the investigational product, whichever is longer); 13. Any other condition deemed by the investigator to make the patient unsuitable for participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Depressive disorder, secondary are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a bone drug plus immune signal stop blood cancer from returning after transplant?
- Can tailored drug dosing make stem cell transplants safer?
- A phone call from a survivor: could peer support calm transplant anxiety?
- Can gut bacteria help rebuild immunity after stem cell transplants?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Could virtual reality help patients recover faster from cell therapy?